Explore Adjuvia’s clinical-stage and partner-ready pipeline
Backed by
And senior pharma angels
The problem
Mitochondrial dysfunction is at the core of many chronic and rare diseases
The unmet need
Damaged mitochondria cause excessive oxidative stress, chronic inflammation, cellular damage and, ultimately, organ failure. Most of these conditions have no effective disease-modifying treatments.
In short
Patients often live with muscle weakness, exhaustion and loss of coordination — and in many cases, organ failure and a shortened life.
Our solution · Meet the molecule
Astaxanthin (asta-ZAN-thin)
The apex carotenoid that colors salmon, shrimp, krill-eating flamingos and the bright orange yolks of insect-eating chickens — and the most powerful antioxidant that exists in nature.
A novel molecular composition of astaxanthin, produced by our patented manufacturing process and incorporated into a proprietary lipid nanoparticle platform. The result is an IND-accepted, pharmaceutical-grade astaxanthin nanoparticle for the treatment of rare mitochondrial diseases — with unprecedented bioactivity and bioavailability compared to over-the-counter astaxanthin supplements.
How it works
Taken by mouth, ATI-105 is broadly absorbed into all tissues and organs — including the brain.
Cells take it up rapidly, and it inserts into cell and mitochondrial membranes.
It mops up harmful reactive oxygen byproducts and bypasses broken links in the energy chain, so cells can keep making the energy they need.
How adjuvia is unique
Neutralizes the harmful byproducts that damage cells.
Supports ATP production, the fuel every cell runs on.
Activates pathways that switch off damaging inflammation.
Helps damaged cells and tissues recover.
The result
Reversal of organ damage, extension of lifespan, and hope for patients suffering from lethal mitochondrial diseases with no meaningful treatment options.
Our platform
The brain is protected by a natural barrier that keeps out most medicines — including promising small molecules and gene therapies — one of the biggest challenges in drug development. In preclinical studies, our proprietary lipid nanoparticle platform solved this problem, enabling efficient delivery of small molecules and nucleic acids to the brain and other target organs — safely, with no toxic or inflammatory side effects.
Learn more about our platformOur wholly-owned pipeline
Advancing ourselves
ATI-105 · Lead · Phase 1
Designed to repair the cell’s damaged powerhouses, so organs like the heart and brain get the energy they need.
ATI-108 · IND-Enabling
Designed to repair damaged mitochondria in eggs and promote successful embryo growth during IVF — giving them a healthier start, as well as the fetal organs the mitochondria will be transferred into.
Available for partnership
ATI-106 · Preclinical
Carries a green tea compound into the brain that may help clear the buildup linked to Alzheimer’s and Parkinson’s, combined with the brain-regenerating properties of our proprietary astaxanthin.
ATI-107 · IND-Enabling
Calms the inflammation that can make LNP delivery of vaccines and gene therapies harder to tolerate, and enables systemic delivery to multiple organs
Featured news
Adjuvia Therapeutics announced today that the first participant has been dosed in its Phase 1 clinical trial of ATI-105, its lead investigational therapeutic candidate for Friedreich’s ataxia (FA). The milestone follows the U.S. Food and Drug Administration's (FDA) acceptance of the company's Investigational New Drug (IND) application in September.
Read the releasePartnering
Our nanoparticle platform carries medicines into the brain and takes the inflammation out of LNP delivery. Two programs are ready for a partner now.
Get in touch